Inclusion Criteria:

- Signed written informed consent

- > or = 18 years of age

- Advanced or metastatic solid tumors:

Part 1: Histologically proven advanced or metastatic solid tumors refractory to standard
therapy or for which no standard therapy exists

Part 2: Histologically proven advanced and/or metastatic solid tumor of one of the
following 6 histologies, that is refractory to standard curative therapy or for which no
curative therapy exists: HCC, NSCLC, gastric cancer, cervical cancer, prostate cancer, and
breast cancer

- Radiologically documented measurable or evaluable (non-measurable) disease

- Adequate performance status and organ function, as evidenced by hematologic and
biochemical blood testing

- Willing to not receive fluoropyrimidine containing chemotherapy for 8 weeks after the
last dose of ADH300004 in this study

Exclusion Criteria:

- Cytotoxic chemotherapy, radiotherapy, or investigational drug within 28 days prior to
study entry

- Non-cytotoxic cancer therapy within 14 days prior to study entry

- Portal hypertension with bleeding esophageal or gastric varices within the past 3
months

- Ascites that is refractory to conservative management

- Inability to take oral medication

- Active peptic ulcer disease

- Known hypersensitivity to 5-FU or ADH300004

- Stroke, major surgery, or other major tissue injury within 30 days before study entry